What did @smoneyyz actually say?
The creator's core argument is that tesamorelin is dangerous for women because it "goes against progesterone and estrogen cycles" and "rapidly spikes IGF-1 levels" in ways that can disrupt ovarian hormone signaling. She claims this could worsen PCOS, endometriosis, and even cause chronic yeast infections. She also argues that ipamorelin combined with CJC-1295 is a gentler, more hormonally compatible alternative, and that tesamorelin's FDA approval was based on male HIV patients, making it a poor fit for women using it for body composition or gym performance.
She draws a secondary point about visceral fat: women store fat differently than men due to estrogen, and stacking tesamorelin with retatrutide could over-target visceral fat to harmful levels, even threatening organ protection.
Does the science back this up?
Partly, but the creator is extrapolating well beyond what the data actually shows, and some specific mechanistic claims are either oversimplified or not supported by published research.
Tesamorelin's FDA approval is indeed grounded in trials conducted predominantly in HIV-positive patients, most of whom were male. The pivotal LHIV-101 and LHIV-102 trials (Falutz et al., 2007, New England Journal of Medicine; Falutz et al., 2010, Annals of Internal Medicine) enrolled mainly men and focused on HIV-associated lipodystrophy. That's a legitimate and underappreciated point.
IGF-1 elevation is real and documented. Tesamorelin does raise IGF-1 levels, and elevated IGF-1 has been associated with altered ovarian function in some research contexts (Giudice et al., 1995, Journal of Clinical Endocrinology and Metabolism). However, the claim that tesamorelin spikes IGF-1 "too rapidly" in a way specifically opposed to the female hormonal cycle is not a conclusion drawn in any peer-reviewed study. That framing is the creator's own interpretive layer, not established endocrinology.
The claim that tesamorelin "goes against" the progesterone and estrogen cycle is presented as fact, but no published mechanistic study in women has demonstrated this directional antagonism. It's a hypothesis, and a plausible one worth studying, but it's not settled science.
What did they get wrong, and what did they get right?
She got the FDA-approval context right. Tesamorelin was not studied in healthy women seeking body composition benefits. That's a valid and underreported point. She's also correct that women have more subcutaneous fat in the lower abdomen than visceral fat, and that estrogen influences fat distribution (Karastergiou et al., 2012, Biology of Sex Differences).
What she got wrong, or at least overclaimed:
- The mechanism by which tesamorelin "goes against" female hormonal cycles is asserted without citation. No published study maps tesamorelin's pulsatile GH release against the luteal or follicular phase in a way that confirms this conflict.
- Linking tesamorelin use to chronic yeast infections is speculative. There is no clinical literature connecting tesamorelin or IGF-1 elevation specifically to recurrent vulvovaginal candidiasis.
- Saying ipamorelin and CJC-1295 "does have some hormonal balancing benefits" for women is equally unsupported by clinical data. She's applying a double standard, criticizing one peptide for lacking female-specific evidence while advocating another with the same evidentiary gap.
- The retatrutide stacking warning is directionally reasonable as a precaution, but the claim that two fat-targeting agents produce an "opposite effect" lacks a specific mechanistic or clinical basis in the literature.
What should you actually know?
The honest answer is that the clinical evidence base for using tesamorelin in healthy, non-HIV women is essentially nonexistent. That alone is a reason to be cautious, and it's a reason the creator identifies correctly, even if she overstates the specific hormonal mechanisms.
IGF-1 does play a role in reproductive hormone signaling. Research has shown IGF-1 receptors are present in ovarian granulosa cells and that IGF-1 modulates follicle-stimulating hormone sensitivity (Zhou et al., 2013, Endocrine Reviews). Whether supraphysiologic IGF-1 from exogenous growth hormone secretagogues disrupts the menstrual cycle in healthy women is an open research question, not a confirmed harm.
Women with PCOS already tend to have elevated IGF-1 sensitivity and altered GH pulsatility (Morales et al., 1996, Journal of Clinical Endocrinology and Metabolism). Adding a potent GH secretagogue in that population without clinical supervision is not a decision anyone should make based on a TikTok, regardless of which creator is making it.
FormBlends strongly recommends consulting a physician familiar with your full hormonal panel before using any growth hormone secretagogue. Blood work, including IGF-1 levels and a menstrual history review, matters here.